Track record · closed signal

Abbott Laboratories (ABT) — closed signal from March 30, 2026

Partial Published before the outcome was known, scored automatically when the window closed on June 28, 2026 — -9% at the close.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted

$100.00 – $105.00Entry zone — fair-value band

$103.41Published — price the day we called it

$113.75Target — the price the thesis aimed for

$104.77Peak — highest point inside the window, not a realized return

$94.12Window close — end-of-window price, context only

What happened

Partial

Reached 13% of the predicted growth at its peak, without hitting the target.

At window close

-9%

realized, from the publication price to the last close inside the window

Peak gain

+1.3%

peak, from the publication price — not a realized return

S&P 500, same window

+15.6%

SPY over the identical days, dividend-adjusted

Window close

$94.12

last close inside the window, ended June 28, 2026

Peak price

$104.77

peak on March 30, 2026 — not a realized return

Days to target

—

The thesis — published March 30, 2026

Predicted growth

+10%

over the measurement window

Target price

$113.75

the price the thesis aimed for

Entry zone

$100.00 – $105.00

the fair-value band we waited for

Price at publication

$103.41

published March 30, 2026

Confidence

71%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Abbott sells devices, tests, nutrition, and medicines and has a mix that helps it hold up in downturns. The company recently added an oncology testing platform, which increases where its tests can be used and gives the commercial story new momentum. Right now overall price action is weak, so the main case is that the stock should first stabilize before investors reward it.

Primary drivers

Broad product mix (devices, tests, nutrition) helps steady sales
New oncology platform increases places where tests can be sold
Debt and cash look manageable, supporting defensive positioning
Price has been weak, creating room for a rebound if momentum firms

How it played out

ABT: the 10% growth thesis missed

Lyra published a 10% growth thesis at $103.41. It expected the stock to stabilize before investors rewarded it. The thesis pointed to Abbott's broad mix of devices, tests, nutrition, and medicines, a new oncology testing platform, manageable debt and cash, and room for a rebound after weak price action.

ABT peaked at $104.77 on March 30, a 1.3% gain. It never reached the $113.75 target. The stock ended the window at $94.12 on June 28. The expected rebound did not happen within the window. The thesis missed.

What happened during the window

On April 16, Abbott reported first-quarter sales of $11.2 billion and adjusted diluted earnings per share of $1.15. On May 27, Abbott announced that Libre Duo had received CE Mark.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals